Michael Dehning, MD
Cardiovascular Disease · Omaha, NENPI 1063473056
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.8% of the total across 200 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 34 manufacturers, the largest accounting for just 11.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $1,636 and has fallen 53.4% since, to $763 in 2025.
Across 200 payments — averaging $25.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$565
- Amgen$548
- Johnson & Johnson$426
- Merck$351
- E.r. Squibb & Sons, L.L.C.$305
- Esperion Therapeutics, Inc.$304
- plus $3K from 28 others
Across 1 payment — averaging $5232.60 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$5K
What the payments were for
- Food & beverage$5,082100%
- Education$80%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 38 | $565 |
| Amgen | 16 | $548 |
| Johnson & Johnson | 13 | $426 |
| Merck | 14 | $351 |
| E.r. Squibb & Sons, L.L.C. | 11 | $305 |
| Esperion Therapeutics, Inc. | 26 | $304 |
| Pfizer | 11 | $249 |
| Boehringer Ingelheim | 10 | $234 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 9 | $195 |
| AstraZeneca | 4 | $168 |
| Medicure Pharma Inc. | 1 | $159 |
| Sanofi-aventis U.S. LLC | 12 | $153 |
| Heartflow, Inc. | 1 | $149 |
| Boston Scientific | 1 | $146 |
| Abbott | 4 | $139 |
| Altathera Pharmaceuticals LLC | 1 | $129 |
| Alnylam Pharmaceuticals Inc. | 1 | $123 |
| Scpharmaceuticals Inc. | 1 | $121 |
| Bridgebio Pharma, Inc. | 1 | $108 |
| Amarin Pharma, Inc. | 5 | $88 |
| Philips North America LLC | 1 | $67 |
| Kiniksa Pharmaceuticals, Ltd. | 4 | $64 |
| Gilead | 3 | $45 |
| Lexicon Pharmaceuticals, Inc. | 1 | $34 |
| Cardiva Medical, Inc. | 1 | $31 |
| Actelion Pharmaceuticals US, Inc. | 2 | $30 |
| Octapharma USA, Inc. | 1 | $26 |
| Regeneron Healthcare Solutions, Inc. | 1 | $23 |
| Medtronic | 1 | $22 |
| Averitas Pharma Inc. | 1 | $21 |
| Zimmer Biomet | 1 | $20 |
| Grifols USA, LLC | 1 | $17 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $17 |
| Pharmacosmos Therapeutics Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Repatha$369
- HMG-CoA reductase inhibitor.$159
- FFRct$149
- WATCHMAN FLX$146
- Sotalol Hydrochloride$129
- CAMZYOS$124
- AMVUTTRA$123
- FUROSCIX$121
- XARELTO$115
- Attruby$108
- VYNDAQEL$107
- LifeVest$104
- VERQUVO$102
- JARDIANCE$101
How this compares
$5,090 in reported general payments places this provider in the 70th percentile of 97 cardiovascular disease providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 149 | $120,528 |
| EntrestoSacubitril/Valsartan | 98 | $81,380 |
| XareltoRivaroxaban | 58 | $52,118 |
| JardianceEmpagliflozin | 49 | $43,207 |
| Repatha SureclickEvolocumab | 50 | $30,673 |
| CorlanorIvabradine Hcl | 12 | $6,065 |
| NexletolBempedoic Acid | 13 | $4,630 |
| Metoprolol Succinate | 313 | $3,030 |
| Flecainide Acetate | 47 | $1,875 |
| Atorvastatin Calcium | 249 | $1,719 |
| Rosuvastatin Calcium | 158 | $1,410 |
| Ezetimibe | 92 | $1,118 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 37 | $503 |
| Spironolactone | 76 | $385 |
| Potassium Chloride | 43 | $365 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $249 | $120,528149 claims |
| NovartisEntresto | $565 | $81,38098 claims |
| Johnson & JohnsonXarelto | $426 | $52,11858 claims |
| Boehringer IngelheimJardiance | $234 | $43,20749 claims |
| AmgenCorlanor | $548 | $6,06512 claims |
| Esperion Therapeutics, Inc.Nexletol | $304 | $4,63013 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 97 cardiovascular disease providers in Nebraska.
Other cardiovascular disease in Omaha
- Ronald ZoltyOmaha$945K
- Jeffrey CarstensOmaha$124K
- John HenryOmaha$79K
- Joseph ThibodeauOmaha$75K
- Qais RadaidehOmaha$50K
- Edward OlearyOmaha$36K
- Faris KhanOmaha$17K
- Michael PetersOmaha$13K
- Thomas PorterOmaha$11K
- Gregory PavlidesOmaha$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.